Nakimuli reportedly drove herself to the facility for what she described as a non-major operation.

On March 27, 2024, the first reading was made in parliament with an Act to enact the National Coffee Act 2021. Act 17 of 2021 aims to dissolve the Coffee Development Authority and transfer its functions to the Ministry responsible for agriculture. This change aligns with the government policy on the rationalization of government agencies and public expenditures.

According to President Museveni’s letter about the rationalization of UCDA, it is fraudulent for UCDA to claim that the big boost in agricultural production is because of its efforts, arguing that since 1991, the year UCDA was formed, by 2013, 68% of the Ugandan homesteads were still outside the money economy, which compelled the government to initiate Operation Wealth Creation.

The Katikkiro’s response gives Buganda’s opinion on the debate over the UCDA amendment bill, which has sparked a broader conversation about the relationship between the central government and Buganda, as well as the implications of the bill for Uganda’s vital coffee sector.

In the recent months, UBOS has been under scrutiny by the public, citing significant errors in tribal population data from the 2024 census provisional report, which the Bureau admitted, saying figures for the Bagisu and Bakiga tribes were mistakenly interchanged.

The National Coffee (Amendment) Bill, 2024, will be carried on to the Bills Committee stage for clause-by-clause scrutiny after 159 members voted in its favor against 77 opposing members.

The Commonwealth Heads of Government Meeting 2024 CHOGM is taking place in Apia, Samoa, and started from October 21-26, 2024, under the theme, One Resilient Common Future: Transforming our Common Wealth. It will be the first CHOGM to be held in a Pacific Small Island Developing State.

Before the government makes any financial commitment to a company, there must be due diligence done, and it is imperative for the government to prioritize accountability in all public expenditures, particularly in high-stakes commitments such as Dei Biopharma Company.